Context Cervical cancer mortality has declined by 74% in the United States since the
implementation of the Papanicolaou (Pap) test. Nevertheless, more than 12 000 US women …

Context The Papanicolaou (Pap) test has indisputably decreased cervical cancer mortality,
as rates have declined by up to 80% in the United States since its implementation. However …

Context.—The limitations of newer cervical screening tests are still being studied. Objective.—
To investigate those limitations, we conducted a retrospective review of 287 cases of …

OBJECTIVE: To characterize the cervical cancers diagnosed following a Pap-negative, high
risk human papillomavirus (HPV)-positive (Pap−/HPV+) screen in routine clinical practice …

Context.—Cervical adenocarcinomas span a diverse group of tumors with several distinct
histologic tumor types, which include endocervical, endometrioid, intestinal, villoglandular …

Background The decrease in incidence of cervical dysplasia and carcinoma has not been as
dramatic as expected with the development of improved research tools and test methods …

Cervical cancer is the second most common cancer in women worldwide and nearly all
cases are human papillomavirus (HPV) related. Pap cytology screening has been very …

Population screening for cervical cancer resulted in significant reduction in the morbidity and
mortality from cervical cancer. An increased understanding of the relationship of HPV …

BACKGROUND Current cervical cancer screening guidelines recommend screening with a
Papanicolaou (Pap) test or by cotesting (Pap and human papillomavirus [HPV]). Given the …

This review will systematically highlight the pros and cons of cervical cancer screening with
HPV (human papillomavirus) testing and cytological methods (Papanicolaou (Pap) test) …